BUZZ-Aldeyra rises as eye disease therapy meets late-stage study goal

Reuters08-08

** Shares of drug developer Aldeyra Therapeutics rise 10.4% to $3.60 premarket

** Co says its experimental therapy to treat dry eye disease met the main goal of a late-stage study

** Dry eye disease affects the layers of tears that cover the cornea causing symptoms like burning, itching and blurred vision

** Co says the therapy reproxalap was statistically superior in reducing the symptom of ocular discomfort in patients

** Trial was designed to satisfy the U.S. FDA's marketing application resubmission requirement - co

** No safety signals were observed in the clinical trial, and reproxalap was well tolerated- ALDX

** The FDA last year rejected the therapy as it did not demonstrate efficacy in treating symptoms of the disease

** Up to last close, stock down 7.1% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment